HALLE (SAALE) / Munich, Germany, 7 May 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish […]
MorphoSys will not execute the option deal to license Vivoryon’s small molecule QPCTL inhibitors for oncology Vivoryon will continue to evaluate QPCTL inhibitors in oncology […]
HALLE (SAALE) / MUNICH and LEIPZIG, Germany, 16 April 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that the Company has entered […]
This is a correction of the announcement from 07:00 am CET March 26, 2020. Reason for the correction: > As of December 31, 2019, the Loss […]
Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) HALLE (SAALE)/MUNICH, Germany, 26 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE007921835), today […]
HALLE (SAALE) / MUNICH, Germany, 19 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Full Year Results for 2019 on Thursday, […]
Vivoryon has extended the trial protocol through the inclusion of exploratory parameters and plans to enroll patients in selected study sites in Denmark, Germany and the […]
HALLE (SAALE)/MUNICH, Germany, 3 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that its management will be presenting at and attending the […]
HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate […]